Trials / Completed
CompletedNCT03806790
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
Detailed description
A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled, parallel-group, open trial of LEO 90100 foam versus Dovobet® ointment (both treatments containing calcipotriol hydrate plus betamethasone dipropionate) in Japanese subjects with psoriasis vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 90100 foam | Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion. |
| DRUG | Dovobet® ointment | Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion. |
Timeline
- Start date
- 2019-01-24
- Primary completion
- 2019-06-10
- Completion
- 2019-06-10
- First posted
- 2019-01-16
- Last updated
- 2025-03-10
- Results posted
- 2020-12-16
Locations
16 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03806790. Inclusion in this directory is not an endorsement.